Samsung Biologics Unveils Two New CDO Platforms

Samsung Biologics announced on the 25th that it has introduced two new Contract Development Organization (CDO) platforms at the ‘2024 Bio Process International (BPI)’ conference, a global bio conference.

BPI is an event where the latest technologies across all areas of biopharmaceutical development, production, and analysis are shared, and partnerships are discussed. It takes place annually in Boston, USA, and this year’s event runs from the 23rd to the 26th of this month.

In a speaking session on the 24th, Samsung Biologics unveiled its new CDO platforms: S-AfuCHO and S-OptiCharge. According to the company, these platforms enhance antibody cancer treatment and enable the production of high-quality proteins, thus increasing customer satisfaction.

S-AfuCHO is an afucosylated cell line platform, where the sugar called 'fucose' is removed. When fucose is absent, antibody-dependent cellular cytotoxicity (ADCC) is strengthened, boosting the immune response. Afucosylated antibodies are used to create more effective antibody drugs for treating diseases like cancer. Samsung Biologics noted that by removing the fucose expression factor in the cell line development phase, the cancer treatment effect is increased by 14 times compared to conventional cell lines.

S-OptiCharge is a platform that can regulate the 'charge variants' of proteins. Charge variants, which occur during the protein manufacturing process, are an important quality attribute (CQA) as they impact the efficacy and stability of biopharmaceuticals, and are therefore subject to regulatory requirements. S-OptiCharge optimizes key process indicators, allowing precise control of charge variants.

A Samsung Biologics representative stated, “With the introduction of S-AfuCHO and S-OptiCharge, our total number of CDO platforms and services has now reached nine. We are also actively promoting our CDO capabilities under the new slogan for the year, 'Fast, Flexible, and Client-Centered.'"